Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

/PRNewswire/ -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative...

Related Keywords

Germany ,Australia ,United States ,Broadmeadows ,New South Wales ,Massachusetts ,Melbourne ,Victoria ,Waltham ,Switzerland ,Jasmin Joller ,Andrew Nash ,Greg Healy ,Kim Odonohue ,Jimmy Baker ,Stage Development Includes Disruptive Innovation ,Twitter ,Drug Administration ,Translational Sciences ,Breakthrough Victoria Fund ,University Of Melbourne ,European Medicines Agency ,Fresenius Medical Care ,New Additions ,Biotech Manufacturing ,Arcturus Therapeutics ,Bill Mezzanotte ,Executive Vice President ,Chief Medical Officer ,External Innovation ,Biotechnology Incubator ,Australia Names Its ,Cicada Innovations ,Melbourne Biomedical ,Victorian Government ,Scientific Officer ,Senior Vice President ,Breakthrough Victoria ,Csl ,